Skip to main content

Table 4 TEAEs of all grades (in ≥ 20% patients) and grade 3/4 severity (in ≥ 5% patients)

From: Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

AE, n (%)

All Grades

(N = 67)

Grade 3/4

(N = 67)

Patients with any AE

65 (97)

60 (90)

Hematologic AE

Platelet count decreased

26 (39)

25 (37)

Red blood cell count decreased

18 (27)

17 (25)

Neutrophil count decreased

17 (25)

16 (24)

White blood cell count increased

17 (25)

7 (10)

Febrile neutropenia

16 (24)

13 (19)

White blood cell count decreased

7 (10)

4 (6)

Non-hematologic AE

Nausea

35 (52)

3 (4)

Constipation

28 (42)

2 (3)

Vomiting

27 (40)

3 (4)

Diarrhea

21 (31)

1 (1)

Fatigue

21 (31)

7 (10)

Hypokalemia

18 (27)

4 (6)

Headache

17 (25)

1 (1)

Decreased appetite

16 (24)

0

Cough

15 (22)

1 (1)

Pyrexia

15 (22)

0

Hypertension

8 (12)

4 (6)

Pneumonia

8 (12)

4 (6)